Avenue Therapeutics, Inc. (ATXI)
USD 1.84
(10.84%)
USD 1.84
(10.84%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.45 Million | -7.59 Million | -3.75 Million | -4.61 Million | -26.25 Million | -18.21 Million |
| Net Income | -10.37 Million | -3.6 Million | -3.73 Million | -5.15 Million | -25.9 Million | -21.54 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 906 Thousand | 649 Thousand | 442 Thousand | 710 Thousand | 1.83 Million | 1.53 Million |
| Change in working capital | -290 Thousand | 408 Thousand | -461 Thousand | -172 Thousand | -2.25 Million | 1.79 Million |
| Other non-cash items | 310 Thousand | -5.05 Million | 909 Thousand | 939 Thousand | 61 Thousand | 412 Thousand |
| Investing Cash Flow | -3 Million | - | - | -1 Million | - | 10 Million |
| Investments in PPE | -3 Million | - | - | -1 Million | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | -5 Million | 10 Million |
| Sales/Maturities of investments | - | - | - | - | 5 Million | 10 Million |
| Other Investing Activities | -3 Million | - | - | -1 Million | - | -10 Million |
| Financing Cash Flow | 7.52 Million | 10.54 Million | 4.38 Million | - | 32.33 Million | -895 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 1.23 Million | -1.1 Million | - | - | - | - |
| Common Stock Issuance | 7.52 Million | 12 Million | 5.04 Million | - | 35 Million | -895 Thousand |
| Other Financing Activities | 7526.00 | -360 Thousand | -663 Thousand | - | -2.66 Million | -895 Thousand |
| Accounts receivables | - | 90 Thousand | -90 Thousand | - | - | - |
| Accounts payables | -360 Thousand | 385 Thousand | -406 Thousand | -229 Thousand | -3.23 Million | 1.12 Million |
| Inventory | - | -90 Thousand | 90 Thousand | - | - | - |
| Other working capital | 70 Thousand | 23 Thousand | -55 Thousand | 57 Thousand | 982 Thousand | 670 Thousand |
| Cash at beginning of period | 6.7 Million | 3.76 Million | 3.13 Million | 8.74 Million | 2.67 Million | 11.78 Million |
| Cash at end of period | 1.78 Million | 6.7 Million | 3.76 Million | 3.13 Million | 8.74 Million | 2.67 Million |
| Capital Expenditure | -3 Million | - | - | -1 Million | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -4.92 Million | 2.94 Million | 631 Thousand | -5.61 Million | 6.07 Million | -9.11 Million |
| Free Cash Flow | -12.45 Million | -7.59 Million | -3.75 Million | -5.61 Million | -26.25 Million | -18.21 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -7.18 Million | -4.34 Million | -10.37 Million | 640 Thousand | 513 Thousand | -4.01 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 192 Thousand | 191 Thousand | 906 Thousand | 307 Thousand | 561 Thousand | 27 Thousand |
| Change in working capital | 162 Thousand | 340 Thousand | -290 Thousand | -911 Thousand | -391 Thousand | -2.82 Million |
| Other non-cash items | 4.65 Million | 491 Thousand | 310 Thousand | -2.36 Million | -1.57 Million | 2.15 Million |
| Investing Cash Flow | - | - | -3 Million | 3 Million | -1 Million | -2 Million |
| Investments in PPE | - | - | -3 Million | 3 Million | -1 Million | -2 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -3 Million | -3 Million | -1000.00 | -2000.00 |
| Financing Cash Flow | 3.97 Million | 4.53 Million | 7.52 Million | 3.94 Million | 479 Thousand | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | 1.23 Million | - | - | - |
| Common Stock Issuance | 4.74 Million | 4.97 Million | 7.52 Million | 3.87 Million | 550 Thousand | - |
| Other Financing Activities | -765 Thousand | -442 Thousand | 7526.00 | 71 Thousand | -71 Thousand | - |
| Accounts receivables | - | - | - | 13 Thousand | 13 Thousand | -13 Thousand |
| Accounts payables | 115 Thousand | 389 Thousand | -360 Thousand | -1.11 Million | 784 Thousand | -942 Thousand |
| Inventory | - | - | - | 974 Thousand | -1 Million | 13 Thousand |
| Other working capital | 47 Thousand | -49 Thousand | 70 Thousand | 190 Thousand | -188 Thousand | -1.88 Million |
| Cash at beginning of period | 3.19 Million | 1.78 Million | 6.7 Million | 161 Thousand | 1.57 Million | 8.23 Million |
| Cash at end of period | 4.91 Million | 3.19 Million | 1.78 Million | 1.78 Million | 161 Thousand | 1.57 Million |
| Capital Expenditure | - | - | -3 Million | 3 Million | -1 Million | -2 Million |
| Effect of forex changes on cash | - | - | - | -1.95 Million | 1.95 Million | - |
| Net cash flow / Change in cash | 1.72 Million | 1.41 Million | -4.92 Million | 1.62 Million | -1.41 Million | -6.66 Million |
| Free Cash Flow | -2.25 Million | -3.12 Million | -12.45 Million | 676 Thousand | -1.88 Million | -6.66 Million |
NG
SHO-PH
WAB
1583
AIS
2382